Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.02 USD | -4.43% | -9.04% | -65.64% |
Financials (USD)
Sales 2024 * | 278M | Sales 2025 * | 372M | Capitalization | 315M |
---|---|---|---|---|---|
Net income 2024 * | -190M | Net income 2025 * | -89M | EV / Sales 2024 * | 1.95 x |
Net Debt 2024 * | 226M | Net Debt 2025 * | 224M | EV / Sales 2025 * | 1.45 x |
P/E ratio 2024 * |
-1.56
x | P/E ratio 2025 * |
-3.41
x | Employees | 597 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.87% |
Latest transcript on Revance Therapeutics, Inc.
1 day | -4.43% | ||
1 week | -9.04% | ||
Current month | -16.34% | ||
1 month | -20.32% | ||
3 months | -45.68% | ||
6 months | -58.46% | ||
Current year | -65.64% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 18-11-04 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 11-02-28 |
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Jill Beraud
BRD | Director/Board Member | 63 | 19-06-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 3.02 | -4.43% | 2,197,279 |
24-05-16 | 3.16 | -4.53% | 2,416,414 |
24-05-15 | 3.31 | -4.89% | 2,559,951 |
24-05-14 | 3.48 | +4.82% | 3,962,235 |
24-05-13 | 3.32 | 0.00% | 2,851,917 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-65.64% | 315M | |
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
+58.05% | 25.73B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B |
- Stock Market
- Equities
- RVNC Stock